ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

hyaluronidase (human recombinant)

Also written as “Efgartigimod PH20 SC”, “efgartigimod PH20 SC” and “rHuPH20”.

Its studies are mostly in Diabetes Mellitus, Type 1 · Myasthenia Gravis · Primary Immunodeficiency Diseases · Dehydration · Multiple Myeloma, led by 7 companies.

Drug pageHyaluronidase (human recombinant): every studyMany companies study it; this page follows only the 57 they lead. All 69 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Oct 7, 202457 company-led studies, 14 open or runningNext primary completion: Mar 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
argenx2211 open or runningphase 4since Oct 7, 2024Feb 20, 2020Mar 2027phase 2 · NCT06655155
Halozyme Therapeuticsits history only200 open or runningphase 4since Apr 4, 2006Apr 4, 2006none ahead
Takedaits history only60 open or runningphase 3since Dec 23, 2008Oct 29, 2008none ahead
Hoffmann-La Rocheits history only42 open or runningphase 2since Sep 11, 2017Sep 11, 2017Aug 31, 2029phase 2 · NCT07503340
Baxter Healthcareits history only30 open or runningphase 4since Dec 10, 2008Dec 10, 2008none ahead
Fosun Pharmaits history only11 open or runningphase 1since Feb 24, 2026Feb 24, 2026none ahead
Johnson & Johnsonits history only10 open or runningphase 1since Aug 6, 2015Aug 6, 2015none ahead

Also a collaborator on its studies: BioLineRx.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of argenx only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 8 studies since Feb 20, 2020.

  1. Feb 14, 2022Phase 3 study in Pemphigoid, BullousNCT05267600 · 98 enrolled · United States, Australia, Bulgaria and more
  2. Dec 8, 2022Phase 3 study in Pemphigoid, BullousNCT05681481 · 64 enrolled · United States, Australia, Bulgaria and more
  3. Jul 28, 2023Phase 3 study in MyositisNCT05979441 · 240 planned · United States, Argentina, Austria and more
  4. Mar 6, 20242 phase 3 studies in Graves OphthalmopathyNCT06307626, NCT06307613
  5. Apr 26, 2024Phase 3 study in Myasthenia GravisNCT06392386 · 12 planned · United States, Australia, Belgium and more
  6. Aug 14, 2024Phase 3 study in Myasthenia GravisNCT06558279 · 141 enrolled · United States, Australia, Austria and more
  7. Oct 7, 2024Phase 4 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNCT06637072 · 23 enrolled · United States
  8. Oct 22, 2024Phase 2 study in Scleroderma, SystemicNCT06655155 · 87 enrolled · United States, Argentina, Belgium and more
  9. Nov 10, 2024Phase 3 study in Primary Sjogrens DiseaseNCT06684847 · 631 enrolled · United States, Argentina, Australia and more
  10. Mar 27, 2025Phase 4 study in New Onset Generalized Myasthenia Gravis (gMG)NCT06909214 · 30 planned · United States
  11. Apr 30, 2026Phase 3 study in Graves DiseaseNCT07570316 · 230 planned · United States, Georgia, United Kingdom
  12. May 13, 2026Phase 3 study in Graves DiseaseNCT07596849 · 230 planned · Belgium, Bulgaria, Canada and more
  13. Jul 29, 2026Phase 2 study in Sjogrens DiseaseNCT07760818 · 75 planned
  14. Oct 19, 2026Primary completion moved from 2026-10-01 to 2027-10Date moved laterphase 3 · +12 months · NCT04812925

Ahead

  1. Mar 2027Primary completion: phase 2 study in Scleroderma, SystemicNCT06655155
  2. Apr 30, 2027Primary completion: phase 2 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNCT04280718
  3. Jul 2027Primary completion: phase 3 study in Primary Sjogrens DiseaseNCT06684847
  4. Sep 2027Primary completion: phase 3 study in Myasthenia GravisNCT06392386

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 22 argenx leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07760818Sjogrens Disease2Not yet recruitingJul 28, 202875
NCT07596849Graves Disease · Belgium, Bulgaria, Canada and more3RecruitingJun 2028230
NCT07570316Graves Disease · United States, Georgia, United Kingdom3RecruitingJun 2028230
NCT06909214New Onset Generalized Myasthenia Gravis (gMG) · United States4RecruitingAug 202630
NCT06684847Primary Sjogrens Disease · United States, Argentina, Australia and more3Active, not recruitingJul 2027631
NCT06655155Scleroderma, Systemic · United States, Argentina, Belgium and more2Active, not recruitingMar 202787
NCT06637072Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States4CompletedFeb 19, 202623
NCT06558279Myasthenia Gravis · United States, Australia, Austria and more3Active, not recruitingJan 12, 2026141
NCT06392386Myasthenia Gravis · United States, Australia, Belgium and more3RecruitingSep 202712
NCT06307626Graves Ophthalmopathy · United States, Austria, Bulgaria and more3TerminatedDec 15, 2025105
NCT06307613Graves Ophthalmopathy · United States, Australia, Belgium and more3TerminatedDec 15, 2025102
NCT05979441Myositis · United States, Argentina, Austria and more3By invitationSep 2028240
NCT05681481Pemphigoid, Bullous · United States, Australia, Bulgaria and more3TerminatedMar 20, 202564
NCT05267600Pemphigoid, Bullous · United States, Australia, Bulgaria and more3CompletedSep 13, 202498
NCT04812925Purpura, Thrombocytopenic, Idiopathic · United States, Argentina, Australia and more3Active, not recruitingOct 2027173
NCT04818671Myasthenia Gravis · United States, Belgium, Czechia and more3CompletedDec 31, 2024184
NCT04735432Myasthenia Gravis · United States, Belgium, Georgia and more3CompletedNov 2, 2021110
NCT04687072Purpura, Thrombocytopenic, Idiopathic · United States, Argentina, Australia and more3CompletedOct 9, 2023207
NCT04598477Pemphigus · United States, Australia, Bulgaria and more3TerminatedMar 25, 2024183
NCT04598451Pemphigus · United States, Australia, Bulgaria and more3CompletedAug 22, 2023222
NCT04564066Healthy Volunteers · Netherlands1CompletedDec 24, 202054
NCT04280718Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Austria, Belgium and more2Active, not recruitingApr 30, 2027229

How it is read

Names in the registry

  • “Efgartigimod PH20 SC”, 12 entries
  • “efgartigimod PH20 SC”, 10 entries
  • “rHuPH20”, 5 entries
  • “Recombinant human hyaluronidase PH20 (rHuPH20)”, 4 entries
  • “recombinant human hyaluronidase”, 3 entries

Codes read as this program: RHUPH20.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.